Anti-cytokine therapy in the treatment of psoriasis

Cytokine

Volumn 61, Issue 3, 2013, Pages 704-712

  Kupetsky, Erine A ^a   Mathers, Alicia R ^a   Ferris, Laura K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

IL 12; IL 17; IL 22; IL 23; TNF

Indexed keywords

ADALIMUMAB; APG 2305; APILIMOD; APREMILAST; BMS 582949; BRIAKINUMAB; BRODALUMAB; CNTO 1959; CYCLOSPORIN A; CYTOKINE ANTIBODY; ETANERCEPT; ETRETIN; FEZAKINUMAB; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 ANTIBODY; IXEKIZUMAB; METHOTREXATE; PLACEBO; SCH 900222; SECUKINUMAB; STEROID; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB;

ADAPTIVE IMMUNITY; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; DRY SKIN; ENZYME INHIBITION; HAIR LOSS; HUMAN; INFECTION; INNATE IMMUNITY; LIVER TOXICITY; LOADING DRUG DOSE; NAUSEA; NEUTROPENIA; NEUTROPHIL; PHOTOTHERAPY; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS; PSORIASIS VULGARIS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TERATOGENICITY; TH17 CELL; ULTRAVIOLET RADIATION; UPPER RESPIRATORY TRACT INFECTION;

CYTOKINES; DERMATOLOGIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; PSORIASIS;

EID: 84875380715     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.12.027     Document Type: Review

References (116)

1. Perera G.K., Di Meglio P., Nestle F.O. Psoriasis. Annu Rev Pathol 2012, 7:385-422.
2. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004, 3:121-128.
3. Patel RV, Lebwohl M. In the clinic. Psoriasis. Ann Intern Med 2011;155:ITC2-1, àíICT2-15;quiz ITC2-16.
4. Javitz H.S., Ward M.M., Farber E., Nail L., Vallow S.G. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002, 46:850-860.
5. Levine D., Gottlieb A. Evaluation and management of psoriasis: an internist's guide. Med Clin North Am 2009, 93:1291-1303.
6. Kikly K., Liu L., Na S., Sedgwick J.D. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006, 18:670-675.
7. Li J., Chen X., Liu Z., Yue Q., Liu H. Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sci Technol Med Sci 2007, 27:330-332.
8. van Beelen A.J., Teunissen M.B., Kapsenberg M.L., de Jong E.C. Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol 2007, 7:374-381.
9. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008, 128:1064-1067.
10. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Farinas M.S., Fuentes-Duculan J., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007, 204:3183-3194.
11. Guttman-Yassky E., Lowes M.A., Fuentes-Duculan J., Zaba L.C., Cardinale I., Nograles K.E., et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008, 181:7420-7427.
12. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
13. Sweeney C., Tobin A.-M., Kirby B. Innate immunity in the pathogenesis of psoriasis. Arch Dermatol Res 2011, 303:691-705.
14. Wagner E.F., Schonthaler H.B., Guinea-Viniegra J., Tschachler E. Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 2010, 6:704-714.
15. Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-[kappa]B pathways. Nat Genet 2009, 41:199-204.
16. Villablanca E.J., Mora J.R. A two-step model for Langerhans cell migration to skin-draining LN. Eur J Immunol 2008, 38:2975-2980.
17. Avramidis G., Krüger-Krasagakis S., Krasagakis K., Fragiadaki I., Kokolakis G., Tosca A. The role of endothelial cell apoptosis in the effect of etanercept in psoriasis. Br J Dermatol 2010, 163:928-934.
18. Gottlieb A.B., Chamian F., Masud S., Cardinale I., Abello M.V., Lowes M.A., et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005, 175:2721-2729.
19. Balato A., Balato B., Megna M., Schiattarella M., Lembo S., Ayala F. Pathogenesis of psoriasis: the role of pro-inflammatory cytokines produced by Keratinocytes. Pathogenesis of psoriasis: the role of pro-inflammatory cytokines produced by keratinocytes 2012, 372. InTech, Shanghai. J. Soung (Ed.).
20. Schmuth M., Neyer S., Rainer C., Grassegger A., Fritsch P., Romani N., et al. Expression of the C-C chemokine MIP-3α/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 2002, 11:135-142.
21. Zaba L.C., Suarez-Farinas M., Fuentes-Duculan J., Nograles K.E., Guttman-Yassky E., Cardinale I., et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009, 124(1022-10):e1-e395.
22. Chiricozzi A., Guttman-Yassky E., Suarez-Farinas M., Nograles K.E., Tian S., Cardinale I., et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011, 131:677-687.
23. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
24. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., et al. Transforming growth factor-[beta] induces development of the TH17 lineage. Nature 2006, 441:231-234.
25. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGF[beta] in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
26. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
27. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
28. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 Helper T Cells. New Engl J Med 2009, 361:888-898.
29. Mathers A.R., Janelsins B.M., Rubin J.P., Tkacheva O.A., Shufesky W.J., Watkins S.C., et al. Differential capability of human cutaneous dendritic cell subsets to initiate Th17 responses. J Immunol 2009, 182:921-933.
30. Goodman W.A., Levine A.D., Massari J.V., Sugiyama H., McCormick T.S., Cooper K.D. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009, 183:3170-3176.
31. Stockinger B., Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007, 19:281-286.
32. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
33. Hoeve M.A., Savage N.D.L., de Boer T., Langenberg D.M.L., De Waal Malefyt R., Ottenhoff T.H.M., et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006, 36:661-670.
34. Ferretti S., Bonneau O., Dubois G.R., Jones C.E., Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003, 170:2106-2112.
35. Villadsen L.S., Schuurman J., Beurskens F., Dam T.N., Dagnaes-Hansen F., Skov L., et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003, 112:1571-1580.
36. Batten M., Li J., Yi S., Kljavin N.M., Danilenko D.M., Lucas S., et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006, 7:929-936.
37. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
38. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
39. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
40. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012, 11:763-776.
41. Laggner U., Di Meglio P., Perera G.K., Hundhausen C., Lacy K.E., Ali N., et al. Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T Cell subset with a potential role in psoriasis. J Immunol 2011, 187:2783-2793.
42. Lin A.M., Rubin C.J., Khandpur R., Wang J.Y., Riblett M., Yalavarthi S., et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011, 187:490-500.
43. Raychaudhuri S.P. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2012.
44. Yawalkar N., Karlen S., Hunger R., Brand C.U., Braathen L.R. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998, 111:1053-1057.
45. Kauffman C.L., Aria N., Toichi E., McCormick T.S., Cooper K.D., Gottlieb A.B., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004, 123:1037-1044.
46. Rizzo H.L., Kagami S., Phillips K.G., Kurtz S.E., Jacques S.L., Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 2011, 186:1495-1502.
47. Krueger J.G., Fretzin S., Suarez-Farinas M., Haslett P.A., Phipps K.M., Cameron G.S., et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012, 130(145-54):e9.
48. Tonel G., Conrad C., Laggner U., Di Meglio P., Grys K., McClanahan T.K., et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol 2010, 185:5688-5691.
49. Belladonna M.L., Renauld J.C., Bianchi R., Vacca C., Fallarino F., Orabona C., et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol 2002, 168:5448-5454.
50. McGeachy M.J., Chen Y., Tato C.M., Laurence A., Joyce-Shaikh B., Blumenschein W.M., et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009, 10:314-324.
51. Bovenschen H.J., van de Kerkhof P.C., van Erp P.E., Woestenenk R., Joosten I., Koenen H.J. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 2011, 131:1853-1860.
52. Chan J.R., Blumenschein W., Murphy E., Diveu C., Wiekowski M., Abbondanzo S., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006, 203:2577-2587.
53. Paul C., Gallini A., Maza A., Montaudie H., Sbidian E., Aractingi S., et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2011, 25(Suppl 2):2-11.
54. Tsuda K., Yamanaka K., Kitagawa H., Akeda T., Naka M., Niwa K., et al. Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells. PLoS One 2012, 7:e31465.
55. Maza A., Montaudie H., Sbidian E., Gallini A., Aractingi S., Aubin F., et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol 2011, 25(Suppl 2):19-27.
56. Elango T., Dayalan H., Subramanian S., Gnanaraj P., Malligarjunan H. Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients. Clin Chim Acta 2012, 413:1652-1656.
57. Meephansan J., Ruchusatsawat K., Sindhupak W., Thorner P.S., Wongpiyabovorn J. Effect of methotrexate on serum levels of IL-22 in patients with psoriasis. Eur J Dermatol 2011, 21:501-504.
58. Dogra S., Krishna V., Kanwar A.J. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study. Clin Exp Dermatol 2012, 37:729-734.
59. Herrier R.N. Advances in the treatment of moderate-to-severe plaque psoriasis. Am J Health Syst Pharm 2011, 68:795-806.
60. Papp K., Cather J.C., Rosoph L., Sofen H., Langley R.G., Matheson R.T., et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012, 380:738-746.
61. Papp K.A., Menter A., Strober B., Langley R.G., Buonanno M., Wolk R., et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012, 167:668-677.
62. A Study of BMS-582949 in: Patients with moderate to severe plaque psoriasis. In: Clinical trials.gov; 2006.
63. Liu C., Lin J., Wrobleski S.T., Lin S., Hynes J., Wu H., et al. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][ 1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases. J Med Chem 2010, 53:6629-6639.
64. Donetti E., Gualerzi A., Ricceri F., Pescitelli L., Bedoni M., Prignano F. Etanercept restores a differentiated keratinocyte phenotype in psoriatic human skin: a morphological study. Exp Dermatol 2012, 21:549-551.
65. Garcia-Valladares I., Cuchacovich R., Espinoza L.R. Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des Dev Ther 2011, 5:41-49.
66. Mitoma H., Horiuchi T., Tsukamoto H., Tamimoto Y., Kimoto Y., Uchino A., et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008, 58:1248-1257.
67. Menter A., Feldman S.R., Weinstein G.D., Papp K., Evans R., Guzzo C., et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007, 56(31):e1-e15.
68. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010, 69:817-821.
69. Wolbink G.J., Vis M., Lems W., Voskuyl A.E., de Groot E., Nurmohamed M.T., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715.
70. Enbrel Prescribing Information Thousand Oaks 2011, Immunex Corporation, CA.
71. Shen C., Assche G.V., Colpaert S., Maerten P., Geboes K., Rutgeerts P., et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005, 21:251-258.
72. Malaviya R., Sun Y., Tan J.K., Wang A., Magliocco M., Yao M., et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 2006, 55:590-597.
73. Bean A.G., Roach D.R., Briscoe H., France M.P., Korner H., Sedgwick J.D., et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999, 162:3504-3511.
74. Fallahi-Sichani M., Flynn J.L., Linderman J.J., Kirschner D.E. Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol 2012, 188:3169-3178.
75. Papp K.A., Tyring S., Lahfa M., Prinz J., Griffiths C.E., Nakanishi A.M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005, 152:1304-1312.
76. Humira Prescribing Information. In: North Chicago, IL: Abbott Laboratories; 2011.
77. Turner D., Picot J., Cooper K., Loveman E. Adalimumab for the treatment of psoriasis. Health Technol Assess 2009, 13(Suppl 2):49-54.
78. Mrowietz U., Kragballe K., Reich K., Griffiths C.E., Gu Y., Wang Y., et al. An Assessment of adalimumab efficacy in three phase III clinical trials using the european consensus programme criteria for psoriasis treatment goals. Br J Dermatol 2012.
79. Solomon D.H., Massarotti E., Garg R., Liu J., Canning C., Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011, 305:2525-2531.
80. Wu J.J., Poon K.Y., Channual J.C., Shen A.Y. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012, 1-7.
81. Benson J.M., Peritt D., Scallon B.J., Heavner G.A., Shealy D.J., Giles-Komar J.M., et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 2011, 3:535-545.
82. Croxtall J.D. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011, 71:1733-1753.
83. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.
84. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684.
85. Wada Y., Cardinale I., Khatcherian A., Chu J., Kantor A.B., Gottlieb A.B., et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PLoS One 2012, 7:e35069.
86. Carmody R.J., Ruan Q., Liou H.C., Chen Y.H. Essential roles of c-Rel in TLR-induced IL-23 p19 gene expression in dendritic cells. J Immunol 2007, 178:186-191.
87. Grumont R., Hochrein H., O'Keeffe M., Gugasyan R., White C., Caminschi I., et al. C-Rel regulates interleukin 12 p70 expression in CD8(+) dendritic cells by specifically inducing p35 gene transcription. J Exp Med 2001, 194:1021-1032.
88. Mason N., Aliberti J., Caamano J.C., Liou H.C., Hunter C.A. Cutting edge: identification of c-Rel-dependent and -independent pathways of IL-12 production during infectious and inflammatory stimuli. J Immunol 2002, 168:2590-2594.
89. Sanjabi S., Hoffmann A., Liou H.C., Baltimore D., Smale S.T. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci U S A 2000, 97:12705-12710.
90. A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in patients with psoriasis. In: clinicaltrials.gov; 2010.
91. A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE). In: Clinicaltrials.gov; 2012.
92. A Study to Determine the Optimal Dose of SCH 900222 for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495 AM2) (MK-3222-003). In: Clinicaltrials.gov; 2012.
93. Gudjonsson J.E., Johnston A., Ellis C.N. Novel systemic drugs under investigation for the treatment of psoriasis. J Am Acad Dermatol 2012, 67:139-147.
94. Mitra A., Fallen R.S., Lima H.C. Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol 2012.
95. Ryan C., Leonardi C.L., Krueger J.G., Kimball A.B., Strober B.E., Gordon K.B., et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011, 306:864-871.
96. Reddy M., Torres G., McCormick T., Marano C., Cooper K., Yeilding N., et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol 2010, 37:413-425.
97. Cheng X., Yu X., Ding Y.J., Fu Q.Q., Xie J.J., Tang T.T., et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008, 127:89-97.
98. Picard C., Fieschi C., Altare F., Al-Jumaah S., Al-Hajjar S., Feinberg J., et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet 2002, 70:336-348.
99. Waisman A. To be 17 again-anti-interleukin-17 treatment for psoriasis. N Engl J Med 2012, 366:1251-1252.
100. The impact of targeted therapy on microorganism in patients with psoriasis. In: Clinicaltrials.gov; 2012.
101. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366:1190-1199.
102. A study in participants with moderate to severe psoriasis. In: Clinical trials.gov; 2010.
103. Papp K.A., Langley R.G., Sigurgeirsson B., Abe M., Baker D.R., Konno P., et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a randomised, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2012.
104. Study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with psoriasis. In: Clinical trials.gov; 2009.
105. Papp K.A., Reid C., Foley P., Sinclair R., Salinger D.H., Williams G., et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012, 132:2466-2469.
106. Papp K.A., Leonardi C., Menter A., Ortonne J.P., Krueger J.G., Kricorian G., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366:1181-1189.
107. Genovese M.C., Van den Bosch F., Roberson S.A., Bojin S., Biagini I.M., Ryan P., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62:929-939.
108. Cho J.S., Pietras E.M., Garcia N.C., Ramos R.I., Farzam D.M., Monroe H.R., et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 2010, 120:1762-1773.
109. Huppler A.R., Bishu S., Gaffen S.L. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther 2012, 14:217.
110. Smeekens S.P., Henriet S.S., Gresnigt M.S., Joosten L.A., Hermans P.W., Netea M.G., et al. Low interleukin-17A production in response to fungal pathogens in patients with chronic granulomatous disease. J Interferon Cytokine Res 2012, 32:159-168.
111. Pan H.F., Li X.P., Zheng S.G., Ye D.Q. Emerging role of interleukin-22 in autoimmune diseases. Cytokine Growth Factor Rev 2012.
112. Study evaluating the safety and tolerability Of ILV-094 In subjects with psoriasis. In: Clinical trials.gov; 2012.
113. Lebwohl M., Bagel J., Gelfand J.M., Gladman D., Gordon K.B., Hsu S., et al. From the medical board of the national psoriasis foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008, 58:94-105.
114. Domm S., Cinatl J., Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008, 159:1217-1228.
115. Smitten A.L., Choi H.K., Hochberg M.C., Suissa S., Simon T.A., Testa M.A., et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007, 57:1431-1438.
116. Billich A. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs 2007, 10:53-59.